Benzinga · Jul 28, 2026
Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1
Leerink Partners analyst Joseph Schwartz upgrades Gossamer Bio (NASDAQ:GOSS) from Market Perform to Outperform and maintains the price target from $1 to $1.

